Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System

Перспективные подходы нанотехнологий в лечении аутоиммунных заболеваний центральной нервной системы
Costas Demetzos, Maria Chountoulesi
2020-06-02

drug delivery nanosystemsexperimental autoimmune encephalomyelitis (EAE)multiple sclerosisnanotechnologytolerance-inducing nanocarriers
Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease of the central nervous system (CNS) that yields to neuronal axon damage, demyelization, and paralysis. Although several drugs were designed for the treatment of MS, with some of them being approved in the last few decades, the complete remission and the treatment of progressive forms still remain a matter of debate and a medical challenge. Nanotechnology provides a variety of promising therapeutic tools that can be applied for the treatment of MS, overcoming the barriers and the limitations of the already existing immunosuppressive and biological therapies. In the present review, we explore literature case studies on the development of drug delivery nanosystems for the targeted delivery of MS drugs in the pathological tissues of the CNS, providing high bioavailability and enhanced therapeutic efficiency, as well as nanosystems for the delivery of agents to facilitate efficient remyelination. Moreover, we present examples of tolerance-inducing nanocarriers, being used as promising vaccines for antigen-specific immunotherapy of MS. We emphasize on liposomes, as well as lipid- and polymer-based nanoparticles. Finally, we highlight the future perspectives given by the nanotechnology field toward the improvement of the current treatment of MS and its animal model, experimental autoimmune encephalomyelitis (EAE).
1
Drug delivery nanosystems enable targeted delivery of MS drugs to pathological CNS tissues, increasing bioavailability and therapeutic efficiency.
2
Liposomes and lipid- and polymer-based nanoparticles are emphasized as key nanotechnology platforms for improving MS and EAE treatment.
3
Nanosystems can deliver agents that facilitate efficient remyelination in MS.
4
Nanotechnology offers therapeutic tools that can overcome limitations of existing immunosuppressive and biological MS therapies.
5
Tolerance-inducing nanocarriers are promising as antigen-specific immunotherapy vaccines for MS.

Nanotechnology-based therapeutic nanosystems (liposomes, lipid- and polymer-based nanoparticles, and tolerance-inducing nanocarriers) for treatment of multiple sclerosis and delivery of remyelination or immunomodulatory agents to the central nervous system

Targeted delivery, bioavailability and therapeutic efficacy of MS drugs and remyelination or antigen-specific tolerance-inducing agents in pathological CNS tissues using nanocarriers to overcome barriers and improve treatment outcomes

Publication Details
Publication Date
2020-06-02
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Costas Demetzos
Maria Chountoulesi
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%